Phase II Study of Consolidation Chemotherapy with Amrubicin after Concurrent Etoposide and Cisplatin plus Accelerated Hyperfractionated Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer.

Phase II Study of Consolidation Chemotherapy with Amrubicin after Concurrent Etoposide and Cisplatin plus Accelerated Hyperfractionated Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer. - Phase II Study of Consolidation Chemotherapy with AMR for LD-SCLC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002352

Enrollment

Registered

2010-10-01

Start date

2009-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

limited-stage small-cell lung cancer

Interventions

consolidation chemotherapy with amrubicin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) histologically or cytologically proven small-cell lung cancer 2) limited-stage 3) chemo-naive 4) age: 20-74 5) PS(ECOG): 0 or 1 6) measurable lesion 7) adequate organ function 8) written informed consent

Exclusion criteria

Exclusion criteria: 1.pericardial effusion 2.active concomitant malignancy 3.severe comorbidity 4.interstitial pneumonia or active lung fibrosis on chest x-ray 5.pregnant or lactating woman 6.history of severe drug allergy 7.psychiatric disorder

Design outcomes

Primary

Measure	Time frame
2-year progression-free survival	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026